QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=2F2A3216137F3E590CE727FF0B4C92D2;jsessionid=E4499CAE265760886C8890F4FD54AAD9;jsessionid=4430919CDFE93F474090CD4BA83EAE18;jsessionid=394EE6AB79B10775F8484E2C4BDECDC2;jsessionid=8C2DA66B013BC80ABFE0B29F3EF47767;jsessionid=41DBD35DD65E74FCAB4424B3FB4E220B (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=0F62AD57107DF9D49BFCDEB9401817EC;jsessionid=2F2A3216137F3E590CE727FF0B4C92D2;jsessionid=E4499CAE265760886C8890F4FD54AAD9;jsessionid=4430919CDFE93F474090CD4BA83EAE18;jsessionid=394EE6AB79B10775F8484E2C4BDECDC2;jsessionid=8C2DA66B013BC80ABFE0B29F3EF47767;jsessionid=41DBD35DD65E74FCAB4424B3FB4E220B